Loading…
Reported covered position: Counsel, Rep. Mollohan
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA |
| 3 |
| 2025–2026 |
| CORVENT MEDICAL, INC. | 2 | 2026 |
| DUKE UNIVERSITY | 2 | 2026 |
| IRHYTHM TECHNOLOGIES INC | 2 | 2025–2026 |
| RAINFALL HEALTH | 2 | 2026 |
| XEROX HOLDINGS CORPORATION (FORMERLY LEXMARK INTERNATIONAL, INC.) | 2 | 2026 |
| DUKE UNIVERSITY HEALTH SYSTEM | 1 | 2025 |
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
CMS TEAM model, value-based care arrangements. CMS CJR-X model.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · 2A
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
CMS TEAM model, value-based care arrangements.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare policies.
National security issues related to pharmaceutical industry, including supply chain.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to university endowment tax.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade policies and agreements, including IP protections, and administrative tariff actions.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Government systems for AI integration. Regulation of AI medical technology.
Government systems for AI integration. Medicare coverage for AI technology.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · first_quarter · 1T
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.
Filing targets: SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Government systems for AI integration.
Government systems for AI integration.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Government systems for AI integration.
Government systems for AI integration.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.
Filing targets: SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare disease.
Issues related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to lung disease and rare disease.
Issues related to lung disease and rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENXBIO INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
AVALYN PHARMA INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to rare disease.
Issues related to rare disease.
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE